Renoprotective Effect of Yiqi Yangyin Huayu Tongluo Formula against Diabetic Nephropathy in Diabetic Rats.

Feng-Li Wang,Yue-Hua Wang,Jian-Guo Qin,Lin Han,Xue-Yun Zhang,Hai-Yan An,Zhi-Qiang Chen,Jiang-Hua Zhang

doi:10.1155/2018/4276052

Abstract

Diabetic nephropathy is developed in 20-40% of patients with diabetes mellitus, and patients with diabetic nephropathy require dialysis and renal transplantation. Traditional Chinese medicine has been widely used in treating patients with diabetic nephropathy in China. However, the detailed mechanisms of traditional Chinese medicine remain unclear. Yiqi Yangyin Huayu Tongluo formula (ZY formula) is a traditional Chinese medicinal formula. Here, we demonstrated kidney protective effect of ZY formula on the rats with diabetic nephropathy. The therapeutic effect of ZY formula on the diabetic nephropathy was almost the same as that of Irbesartan, which proved to have excellent curative effects on diabetic nephropathy. We also demonstrated the mechanism of ZY formula effect on the diabetic nephropathy. First, we validated that the activation of ROS-JNK signaling pathway in diabetic rats could be reduced by ZY. Furthermore, collagen I expression could be downregulated by ZY formula treatment. Meanwhile, cell apoptosis in the kidney of diabetic rats could be alleviated by ZY formula.

Highlights

Diabetic nephropathy (DN), a leading cause of end-stage renal disease worldwide, is the main microvascular complication of type II diabetes mellitus [1]
To validate whether the DN of rats could be induced by STZ and the effect of ZY formula on the regulation of urinary protein, we first examined the level of urinary protein of all the rats
The level of urinary protein between the ZY group and Irbesartan group did not show significant difference (Figure 1). This meant the effect of ZY formula and Irbesartan in reducing urinary protein level of diabetic rats was similar

Summary

Introduction

Diabetic nephropathy (DN), a leading cause of end-stage renal disease worldwide, is the main microvascular complication of type II diabetes mellitus [1]. DN is developed in 20-40% of patients with diabetes mellitus, and patients with DN require dialysis and renal transplantation [2]. The characteristic of DN is the persistent albuminuria, accompanied by a progressive elevation of blood pressure, a reduction in glomerular filtration rate, and a reduced risk of cardiovascular events [4]. Both the slowdown of the progression toward end-stage renal disease (ESRD) and the decrease of glomerular filtration rate are closely related to the reduction of albuminuria level. The end point for renoprotection could be indicated by the decline in albuminuria [5]

Methods

Results

Conclusion